The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials

Sanyal, Arun J., Harrison, Stephen A., Ratziu, Vlad, Abdelmalek, Manal F., Diehl, Anna Mae, Caldwell, Stephen, Shiffman, Mitchell L., Aguilar Schall, Raul +11 more·2019·Hepatology

DOI 10.1002/hep.30664

Cited by (390)

Items 301–390 of 390

Liver and spleen stiffness as assessed by vibration controlled transient elastography for diagnosing clinically significant portal hypertension in comparison with other elastography-based techniques in adults with chronic liver disease
Luka Vranić, Tin Nadarević, Davor Štimac, Mirella Fraquelli, Cristina Manzotti, Giovanni Casazza, Agostino Colli · 2022 · Cochrane Database of Systematic Reviews
A Real-World Experience Utilizing the FAST Score to Identify Patients With Nonalcoholic Steatohepatitis Fibrosis
Gres Karim, Dewan Giri, Brooke E. Wyatt, Amreen M. Dinani · 2024 · Gastro Hep Advances
Medical Approach for Weight Loss in Nonalcoholic Fatty Liver Disease
Albert Do, Ysabel C. Ilagan‐Ying, Wajahat Zafar Mehal · 2019 · Current Hepatology Reports
Quantification of gastric mucosal microcirculation as a surrogate marker of portal hypertension by spatially resolved subdiffuse reflectance spectroscopy in diagnosis of cirrhosis: a proof-of-concept study
Arpan Mohanty, Adam Eshein, Phanisyam Kamineni, Uri Avissar, Charles M. Bliss, Michelle T. Long, Robert Lowe, T. Carlton Moore, David Nunes, Vadim Backman et al. · 2020 · Gastrointestinal Endoscopy
Plasma Heparin Cofactor II Activity Is Inversely Associated with Hepatic Fibrosis of Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus
Tomoyo Hara, Ryoko Uemoto, Akiko Sekine, Yukari Mitsui, Shiho Masuda, Hiroki Yamagami, Kiyoe Kurahashi, Sumiko Yoshida, Toshiki Otoda, Tomoyuki Yuasa et al. · 2022 · Journal of Atherosclerosis and Thrombosis
Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) in People with Diabetes: The Need for Screening and Early Intervention. A Consensus Statement of the American Diabetes Association.
Kenneth J. Cusi, Manal F. Abdelmalek, Caroline Margaret Apovian, Kirthikaa Balapattabi, Raveendhara R. Bannuru, Diana Barb, Joan K. Bardsley, Elizabeth Ann Beverly, Karen D. Corbin, Nuha A. ElSayed et al. · 2025
Portal hypertension: recommendations for diagnosis and treatment. Consensus document sponsored by the Spanish Association for the Study of the Liver (AEEH) and the Biomedical Research Network Center for Liver and Digestive Diseases (CIBERehd)
Agustı́n Albillos, Rafael Bañares, Virginia Hernández–Gea · 2024 · Revista Española de Enfermedades Digestivas
Advances in portal hypertension management: Evolution of the Baveno guidelines
Michał Brzdęk, Krystyna Dobrowolska, Jakub Janczura, Małgorzata Wajdowicz, Kinga Brzdęk, Dorota Zarębska‐Michaluk, Anita Gąsiorowska, Alessandra Mangia · 2025 · World Journal of Gastroenterology
Serial measurements of NIS2+® enable monitoring disease evolution in patients with MASH: A retrospective cohort analysis
Arun Jayant Sanyal, Vlad Ratziu, Yacine Hajji, Jérémy Magnanensi, Sylvie Deledicque, Zouher Majd, Dean W. Hum, Bart Staels, Margery A. Connelly, Sven Francque et al. · 2025 · Hepatology Communications
Liver and spleen stiffness as assessed by vibration-controlled transient elastography for diagnosing clinically significant portal hypertension in comparison with other elastography-based techniques in adults with chronic liver disease
Luka Vranić, Tin Nadarević, Davor Štimac, Mirella Fraquelli, Cristina Manzotti, Giovanni Casazza, Agostino Colli · 2026 · Cochrane Database of Systematic Reviews
Real-world quality of life and healthcare resource utilization in patients with metabolic dysfunction-associated steatohepatitis
Jens Uwe Marquardt, Riku Ota, Giada Sebastiani, Diego Moreno Baca, Eliza Smith, Hayley Wallinger, Kathryn W. Tebbs, Emily Quiñones, Lena Amari, Elisabetta Bugianesi · 2026 · JHEP Reports
Restoring Mitochondrial Homeostasis: Therapeutic Strategies for Metabolic Dysfunction-Associated Fatty Liver Disease
J. Morgado, Ivo F. Machado, Anabela Pinto Rolo, Carlos M. Palmeira · 2026 · International Journal of Molecular Sciences
Metabolic Dysfunction-Associated Steatohepatitis (MASH)-Cirrhosis Clinical Trials: Lessons Learned and Future Directions
Rashmee Patil, Winston Dunn, Mazen Noureddin, Naim Alkhouri · 2026 · Drugs
Heterogeneous associations of regional adipose depots with liver fibrosis in U.S. adults
Kuan-Yu Lai, Ci Wang, Hsian-Han Kao, Wen‐Yuan Lin, Tsung‐Po Chen · 2026 · Metabolism Open
Noninvasive surrogate endpoints of adverse outcomes, disease progression, and treatment efficacy in metabolic dysfunction–associated steatohepatitis (MASH)
Arun Jayant Sanyal, Manal F. Abdelmalek, Rohit Seth Loomba · 2026 · Hepatology
Noninvasive Tests for Predicting Decompensation in Compensated Advanced Chronic Liver Disease: A Comprehensive Review
Audrey Payancé, Pierre‐Emmanuel Rautou, Jérôme Boursier, Laurent Castéra, Dominique Charles Valla, Laure Elkrief · 2026 · Liver International
Contemporary epidemiology of metabolic dysfunction-associated steatotic liver disease
Do Han Kim, Donghyun Ko, Aijaz Ahmed, Donghee Kim · 2026 · Expert Review of Gastroenterology & Hepatology
Progression of MASH to cirrhosis, decompensation, and mortality, and the utility of NITs for detection and risk stratification
Philip Noel Newsome, Claudio Sartini, Heather Morris, Derek R. Gazis, Andrea R. Mospan, A. Sidney Barritt, Michael W. Fried, Salvador Augustín, Mandy Fraessdorf, Bryan Rudolph et al. · 2026 · Hepatology Communications
Dyslipidaemia and hepatic steatosis: mechanisms and implications for lipid-lowering therapy
Maurizio Averna, M. Mahmood Hussain, Giuseppe Danilo Norata · 2026 · Nature Reviews Cardiology
#FGDebate: Should we focus on detecting patients at risk of liver disease in the community?
Kushala W. M. Abeysekera, Jessica Shearer, Oliver D. Tavabie, John Francis Dillon, Ian A.C. Rowe · 2022 · Frontline Gastroenterology
Pioneering the path to NASH biomarker approval
Aleksander Ahm Krag, Mary Eugenia Rinella · 2023 · Nature Medicine
Multifactorial Aspects Influencing Non-Alcoholic Fatty Liver Disease (Nafld)
Rachana Raveendran Rachana Raveendran, A. Josephine Josephine. A, P Kalaiselvi Kalaiselvi P, Sureka Varalakshmi, Kanchana S B Kanchana SB, Thahira Abdulla Abdulla Thahira, Swathi T Swathi T, Pinchulatha K Pinchulatha K, Ambili PV Ambili PV, D Roy · 2023 · Journal Of Advanced Zoology
Esteatosis hepática metabólica
Paula Iruzubieta, M. Arias, María Del Barrio, Victor Echavaría, Marta Alonso‐Peña, Javier Crespo · 2024 · Medicine - Programa de Formación Médica Continuada Acreditado
Natural history of nonalcoholic fatty liver disease
Dominic Crocombe, Emmanuel A. Tsochatzis · 2024 · Elsevier eBooks
Zinc supplementation to improve prognosis in patients with compensated advanced chronic liver disease: a multicenter, randomized, double-blind, placebo-controlled clinical trial
Juan Bañares, Laia Aceituno, Lourdes Ruiz‐Ortega, Mònica Pons, Juan G. Abraldeṣ, Joan Genescà · 2024 · Hepatology Communications
Abbreviated Multiparametric MR Solution (the “Liver Triple Screen”), the Future of Non-Invasive MR Quantification of Liver Fat, Iron, and Fibrosis
Gavin Low, Ryan K. W. Chee, Yu Jun Wong, Puneeta Tandon, Florin Manolea, Stephanie Locas, Craig Ferguson, Wendy Tu, Mitchell Patrick Wilson · 2024 · Diagnostics
Resmetirom for Steatotic Liver Disease: Does Data Support Widespread Use?
Winston Dunn, Naim Alkhouri · 2025 · Current Gastroenterology Reports
We are Not Meeting the Needs of Pharmacoeconomic Models of Nonalcoholic Steatohepatitis, But We Can
Elliot B. Tapper, Jagpreet Chhatwal · 2020 · PharmacoEconomics
Optimizing patients with non-alcoholic fatty liver disease pre-transplant
Amine Benmassaoud, Marc Deschênes, Tianyan Chen, Peter Ghali, Giada Sebastiani · 2020 · Canadian Liver Journal
A Path Toward Improving Nonalcoholic Fatty Liver Disease Care Among Non-hepatologists
Suthat Liangpunsakul · 2022 · Endocrine Practice
Underestimation of portal pressures by wedge hepatic venous pressures in patients with non-alcoholic steatohepatitis related cirrhosis- Possibilities and implications
Sanchit Sharma, Abhinav Anand, Anoop Saraya · 2020 · Journal of Hepatology
Quark-gluon interaction in the infrared region of QCD and chromomagnetic moments of quarks
B.A. Arbusov, E. Boos, S.S. Kurennoi, K. Sh. Turashvili · 1985 · OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information)
Smart phone application to exclude esophageal/cardio-fundal varices in compensated cirrhosis of non-viral aetiology using liver transaminases levels and transient elastography measured liver stiffness and splenic stiffness
AAN Nishad, Madunil Anuk Niriella, AP De Silva, Hishali Jayasundara, Vajira Tharanga Samarawickrama, Hiruni Jayasena, Kunchana Thebuwana, Selani Dharshika, G Hewathanthri, CK Ranawaka et al. · 2022 · medRxiv
Safety and efficacy of FGF21 analogs in nonalcoholic steatohepatitis: a meta-analysis of randomized clinical trials
Milene Vitória Sampaio Sobral, Hilária Saugo Faria, Lucas Cael Azevedo Ramos Bendaham, Barbara Bombassaro Masiero, Celine Almeida Gouvêa, Giovana de Souza Faria, Marciane Dias dos Santos, Clara de Andrade Pontual Peres, Lídia Ovileira, Eduardo Souto · 2024
The Impact of Omega-3 Fatty Acids on Triglyceride Levels in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-Analysis of Randomized Controlled Trials with Subgroup Analysis by Diabetes Status
Li, Lan, Cong, Cong, Zhang, Xiaolan, Zhang, Xiaoxia · 2026 · Diabetes, Metabolic Syndrome and Obesity
Relationship Between BMI Degree and Non-Alcoholic Fatty Liver Disease Risk Factors
Chairunnisa Fitri Marpaung, Gontar Alamsyah Siregar, Ilhamd · 2021 · Journal of Endocrinology Tropical Medicine and Infectiouse Disease (JETROMI)
Research progress of sinusoidal endothelial cells in nonalcoholic fatty liver disease
Jielu Cao, Junbin Yan, Jinting Wu, Zhiyun Chen · 2021 · World Chinese Journal of Digestology
Natürlicher Verlauf
Münevver Demir, Hans‐Michael Steffen · 2022 · Springer eBooks
Evaluation of the Effect of CSPH, Reduction of HVPG, and Other Factors Predicting the First Decompensation in Cirrhosis
Dhiraj Tripathi, Càndid Villanueva, Jaime Bosch · 2022 · Springer eBooks
Therapies for Alcohol-Related Liver Disease and for Non-Alcoholic Fatty Liver Disease
Hitoshi Yoshiji, Tadashi Namisaki, Kosuke Kaji, Sven Francque · 2022 · Springer eBooks
Lifestyle treatment in the regression of NASH: insulin resistance, lipid synthesis, and methodological innovation
Justine M. Mucinski · 2022
Noninvasive assessment of liver disease severity: image-related
Kevin Kim‐Jun Teh, Jason Pik‐Eu Chang, George Boon‐Bee Goh · 2023 · Elsevier eBooks
Liver Biopsy and Pressure Hemodynamics: IR Perspective
Aakash Jain, Joseph A. Hughes III, Sidhartha Tavri · 2023 · Digestive Disease Interventions
Methods for assessing portal hypertension
Serge Chooklin, S.S. Chuklin · 2023 · EMERGENCY MEDICINE
Clinical diagnosis and evaluation pathway
Robert Lam, Bubu A. Banini, Albert Do, Joseph K. Lim · 2024 · Elsevier eBooks
Global, Regional, and National Burden of Primary Liver Cancer Among Middle-Aged and Elderly Populations from 2000 to 2021 with a Prediction to 2050
Wei Wang, Yongqiang Xiong, Na Huang, Jun Li, Shu Zhang · 2025 · SSRN Electronic Journal
Hallazgos por imagen de las enfermedades hepáticas por depósito
A.C. Igual Rouilleault, Sara Montoya Jiménez, J. Moreno, E. Belmonte, J.R. Ayuso, Ángeles García‐Criado · 2025 · Radiología
Hepatic isomiR landscaping reveals new biological insights into metabolic dysfunction in steatotic liver disease
Christian Brion, Stephen Aurelien Hoang, Guangliang Wang, Faridodin Mirshahi, Jessie Ang, Matthew Long, Zhu Zheng, Bhanu Sakhamuri, Molly A. Srour, Mohammad Shadab Siddiqui et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
Diagnosis and Monitoring of Metabolic Dysfunction Associated with Fatty Liver Disease in Primary Care Patients with Risk Factors—EsteatoGal Study
Nerea Sánchez-Varela, Sergio Cinza‐Sanjurjo, Tatiana Danif-Ferreira, L. Araújo, Diego Gabriel Mosteiro-Miguéns, Daniel Rey Aldana, Manuel Portela‐Romero, on behalf of the EsteatoGal Researchers · 2025 · Journal of Clinical Medicine
Prognostic Scores in the Management of MASH Related Cirrhosis
Angus W. Jeffrey, Leon Anton Adams, James Chen, Chloe Attree, Avik Majumdar, Luis Calzadilla Bertot · 2025 · Current Hepatology Reports
Safety and Efficacy of FGF21 Analogues in Nonalcoholic Steatohepatitis: A Meta-Analysis of Randomized Clinical Trials
Milene Vitória Sampaio Sobral, Hilária Saugo Faria, Lucas Cael Azevedo Ramos Bendaham, Barbara Bombassaro Masiero, Celine Almeida Gouvêa, Giovana de Souza Faria, Marciane Dias dos Santos, Clara de Andrade Pontual Peres, Larissa Marrocos de Oliveira, Eduardo Buzatti Souto · 2025 · American Journal of Therapeutics
Kommentar zu: „Efruxifermin bei metabolisch bedingter Steatohepatitis mit Leberzirrhose“
Andreas Geier · 2025 · Gastroenterologie up2date
The pathophysiological role of portal hypertension in metabolic dysfunction–associated steatotic liver disease
Søren Møller, Sannia Mia Svenningsen Sjöstedt, Lise Hobolth, Christian Mortensen, Nina Kimer · 2025 · Hepatology Communications
Metabolic dysfunction-associated steatotic liver disease: Role in the development of comorbid conditions and therapeutic management
Tatiana Yu. Demidova, Victoria V. Titova, A. N. Levitskaya, M. A. Gyozalyan · 2025 · Meditsinskiy sovet = Medical Council
Additional file 6 of The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank
Theresa Hydes, Oliver John Kennedy, Buchanan, Ryan, Cuthbertson, Daniel J., Julie Parkes, Fraser, Simon D. S., Roderick, Paul · 2023 · Figshare
Additional file 10 of The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank
Theresa Hydes, Oliver John Kennedy, Buchanan, Ryan, Cuthbertson, Daniel J., Julie Parkes, Fraser, Simon D. S., Roderick, Paul · 2023 · Figshare
Additional file 12 of The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank
Theresa Hydes, Oliver John Kennedy, Buchanan, Ryan, Cuthbertson, Daniel J., Julie Parkes, Fraser, Simon D. S., Roderick, Paul · 2023 · Figshare
Additional file 6 of The triglyceride glucose-body mass index: a non-invasive index that identifies non-alcoholic fatty liver disease in the general Japanese population
Hu, Haofei, Han, Yong, Cao, Changchun, Yongcheng He · 2022 · Figshare
Additional file 5 of The triglyceride glucose-body mass index: a non-invasive index that identifies non-alcoholic fatty liver disease in the general Japanese population
Hu, Haofei, Han, Yong, Cao, Changchun, Yongcheng He · 2022 · Figshare
Additional file 1 of The triglyceride glucose-body mass index: a non-invasive index that identifies non-alcoholic fatty liver disease in the general Japanese population
Hu, Haofei, Han, Yong, Cao, Changchun, Yongcheng He · 2022 · Figshare
Additional file 7 of The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank
Theresa Hydes, Oliver John Kennedy, Buchanan, Ryan, Cuthbertson, Daniel J., Julie Parkes, Fraser, Simon D. S., Roderick, Paul · 2023 · Figshare
Additional file 3 of The triglyceride glucose-body mass index: a non-invasive index that identifies non-alcoholic fatty liver disease in the general Japanese population
Hu, Haofei, Han, Yong, Cao, Changchun, Yongcheng He · 2022 · Figshare
Additional file 1 of The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank
Theresa Hydes, Oliver John Kennedy, Buchanan, Ryan, Cuthbertson, Daniel J., Julie Parkes, Fraser, Simon D. S., Roderick, Paul · 2023 · Figshare
Additional file 3 of The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank
Theresa Hydes, Oliver John Kennedy, Buchanan, Ryan, Cuthbertson, Daniel J., Julie Parkes, Fraser, Simon D. S., Roderick, Paul · 2023 · Figshare
Additional file 4 of The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank
Theresa Hydes, Oliver John Kennedy, Buchanan, Ryan, Cuthbertson, Daniel J., Julie Parkes, Fraser, Simon D. S., Roderick, Paul · 2023 · Figshare
Additional file 7 of The triglyceride glucose-body mass index: a non-invasive index that identifies non-alcoholic fatty liver disease in the general Japanese population
Hu, Haofei, Han, Yong, Cao, Changchun, Yongcheng He · 2022 · Figshare
Additional file 2 of The triglyceride glucose-body mass index: a non-invasive index that identifies non-alcoholic fatty liver disease in the general Japanese population
Hu, Haofei, Han, Yong, Cao, Changchun, Yongcheng He · 2022 · Figshare
Additional file 8 of The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank
Theresa Hydes, Oliver John Kennedy, Buchanan, Ryan, Cuthbertson, Daniel J., Julie Parkes, Fraser, Simon D. S., Roderick, Paul · 2023 · Figshare
Additional file 4 of The triglyceride glucose-body mass index: a non-invasive index that identifies non-alcoholic fatty liver disease in the general Japanese population
Hu, Haofei, Han, Yong, Cao, Changchun, Yongcheng He · 2022 · Figshare
Additional file 1 of Estimates and trends of the global burden of NASH-related liver cancer attributable to high fasting plasma glucose in 1990–2019: analysis of data from the 2019 Global Burden of Disease Study
Li, Ziyi, Na Yang, He, Liyun, Wang, Jialu, Ping, Fan, Wei Li, Xu, Lingling, Zhang, Huabing, Yuxiu Li · 2023 · Figshare
Additional file 9 of The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank
Theresa Hydes, Oliver John Kennedy, Buchanan, Ryan, Cuthbertson, Daniel J., Julie Parkes, Fraser, Simon D. S., Roderick, Paul · 2023 · Figshare
Additional file 5 of The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank
Theresa Hydes, Oliver John Kennedy, Buchanan, Ryan, Cuthbertson, Daniel J., Julie Parkes, Fraser, Simon D. S., Roderick, Paul · 2023 · Figshare
Additional file 2 of The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank
Theresa Hydes, Oliver John Kennedy, Buchanan, Ryan, Cuthbertson, Daniel J., Julie Parkes, Fraser, Simon D. S., Roderick, Paul · 2023 · Figshare
Additional file 13 of The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank
Theresa Hydes, Oliver John Kennedy, Buchanan, Ryan, Cuthbertson, Daniel J., Julie Parkes, Fraser, Simon D. S., Roderick, Paul · 2023 · Figshare
Additional file 11 of The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank
Theresa Hydes, Oliver John Kennedy, Buchanan, Ryan, Cuthbertson, Daniel J., Julie Parkes, Fraser, Simon D. S., Roderick, Paul · 2023 · Figshare
Management of Portal Hypertension
Nicolas Chong Lugon, Guadalupe García–Tsao · 2025 · Springer eBooks
Viscosity Imaging for Detection of Liver Inflammation: A Systematic Review
Atul Kapoor · 2025 · International Journal of Gastroenterology
Comparison of the triglyceride-glucose index and triglyceride-glucose-body mass index for predicting non-alcoholic fatty liver disease in elderly diabetic patients
Gaohui Zhu, Yihui Qu, Kanan Chen, Dingfa He, Jing Wang, Ziwei Tang, Xinyi Wang, Minqiao Zhang, Peilan Jiang, Ruijie Zhang et al. · 2026 · PLoS ONE
Noninvasive Testing for Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Markos Kalligeros, Laurent Castéra, Emmanuel A. Tsochatzis, Naim Alkhouri · 2026 · Clinics in Liver Disease
MRI-derived visceral adipose tissue quantification enhances stratification of nonalcoholic steatohepatitis severity and fibrosis in obesity
Xin Yu, Yinglong Li, You‐Zhen Feng, Zhong‐Yuan Cheng, Bin Sun, Xiang-Ran Cai · 2026 · Abdominal Radiology
Effect of nonalcoholic fatty liver disease on post-myocardial infarction cardiac remodeling
Louise Biquard · 2022 · theses.fr (ABES)
Liver Fibrosis Estimated Using Noninvasive Blood Biochemical Indices Is Correlated with Visit-to-Visit Glycated Hemoglobin A1c Variability in Individuals with Type 2 Diabetes
Yousuke Kaneko, Taiki Hori, Kohsuke Miyataka, Takahito Asai, Tomoyo Hara, Hiroki Yamagami, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Shingen Nakamura et al. · 2026 · Biomedicines
Imaging findings of hepatic storage diseases
A.C. Igual Rouilleault, S. Jiménez, J A Moreno, E. Belmonte, Juan Ramón Ayuso, Ángeles García‐Criado · 2026 · Radiología (English Edition)
Efficacy of tirzepatide versus SGLT2 inhibitors in metabolic dysfunction-associated steatotic liver disease (MASLD): a multicenter propensity-matched real-world study
Ibrahim Khalil, Pallab Sarker, Nabila Nur, M Sahadat Hossain, Aizaz Anwar Khalid, Sajjad Ghanim Al-Badri, Mst. Mahmuda Akter, Manisha Das, Mohd Turzo Rahman · 2026 · Hepatology International
Prognostic value of liver histology in steatotic liver disease: a systematic literature review and meta-analysis
Alfred Sidney Barritt, Anila Qasim, Yestle Kim, Sally D. Miller, John O’Donnell, Karissa Johnston · 2026 · Journal of Comparative Effectiveness Research
International expert panel review for the use of resmetirom and semaglutide in the management of MASH-related fibrosis: clinical practice update
Maria Mironova, Vlad Ratziu, Mary Eugenia Rinella, Meena B. Bansal, Mazen Noureddin, Naim Alkhouri, Quentin Mark Anstee, Philip Noel Newsome, Jörn Markus Schattenberg, Arun Jayant Sanyal et al. · 2026 · Gut
Aligned ELF and VCTE cutoffs facilitate risk staging in patients with metabolic dysfunction-associated steatohepatitis
Matthew F. W. Gee, Andrew N. Billin, Donald B. Chalfin, Rachel K. Fonstad, Edward Bentz Devol, Jordan J. Feld, Keyur Patel, Arun Jayant Sanyal · 2026 · JHEP Reports
Embedding metabolic dysfunction–associated steatotic liver disease fibrosis risk stratification within pharmacist-integrated diabetes comanagement in primary care
Ryan P. Wexler, JEREMY I. CHIMENE-WEISS, Courtney Cameron, Sandra Schipelliti, Pavan Vuddanda, Aileen Roman, Arpan Mohanty · 2026 · Journal of Managed Care & Specialty Pharmacy
Regenerative failure in metabolic dysfunction-associated steatohepatitis: The entrapped progenitor model and precision repair
Dhruv Gehlot, Swayam Bakriwala, Yash Dharmendra Patel · 2026 · Annals of the National Academy of Medical Sciences (India)
Metabolic Dysfunction‐Associated Steatotic Liver Disease
Fasiha Kanwal, Vincent Wai Sun Wong · 2026 · Wiley eBooks